OneChain Immunotherapeutics is an innovative biotech company based in Barcelona (Spain) and focused on the development of CAR T therapies for the treatment of oncological diseases, including a highly novel and differentiated in vivo CAR-T platform.

In vivo CAR-T represents the future of CAR-T therapeutics. Our proprietary next-generation lentiviral vector-based in vivo CAR-T platform has been developed to address the limitations of current platforms. It demonstrates highly efficient specific transfer to multiple immune cell types, with no detectable delivery to off-target tissues.

OneChain is advancing a diversified portfolio of next-generation CAR T technologies, including several candidates that expand our therapeutic pipeline and long-term innovation strategy.

Our lead program is a novel and selective CAR-T therapy against CD1a (OC-1) for the treatment of refractory/relapsed patients with cortical T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma (co T-ALL), a T-ALL subgroup without many options to date. OC-1 is currently under evaluation in a phase 1 clinical trial to assess the safety and efficacy of the therapy (CARxALL clinical trial), where multiple responses have been seen. OC-1 has been granted Orphan Drug Designation for ALL by the EMA and the FDA.